Prediction of oral drug absorption in humans - From cultured cell lines and experimental animals

Expert Opinion on Drug Metabolism and Toxicology

Volumn 4, Issue 5, 2008, Pages 581-590

  Cheng, Kuo Chi ^a   Li, Cheng ^a   Uss, Annette S ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Animal absorption; Caco 2 permeability system; Cell monolayer permeability model; Preclinical animal PK; Prediction of human absorption

Indexed keywords

ACARBOSE; ACICLOVIR; ATENOLOL; CAPTOPRIL; CHLORPROMAZINE; COUMARIN; DOXAZOSIN; DOXORUBICIN; DROLOXIFENE; FLUINDOSTATIN; FLUNISOLIDE; FUROSEMIDE; GANCICLOVIR; ISOXEPAC; KETANSERIN; MACROGOL 4000; MANNITOL; MENOGARIL; METOPROLOL; MIGLITOL; MOXIFLOXACIN; NADOLOL; NIMODIPINE; OMEPRAZOLE; PELRINONE; PROPRANOLOL; RAMIPRIL; REMOXIPRIDE; TERBUTALINE; UNINDEXED DRUG;

ANATOMICAL VARIATION; CELL CULTURE; CELL LINE; CELL STRAIN CACO 2; CONCENTRATION RESPONSE; DOG; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EXPOSURE; DRUG METABOLISM; DRUG PENETRATION; DRUG SCREENING; EXPERIMENTAL ANIMAL; EXPERIMENTAL RAT; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; INTESTINE ABSORPTION; MONKEY; NONHUMAN; PREDICTION; REVIEW; SPECIES DIFFERENCE;

ANIMALS; CACO-2 CELLS; CELL LINE; HUMANS; INTESTINAL ABSORPTION; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; SPECIES SPECIFICITY;

ANIMALIA;

EID: 45949101019     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.4.5.581     Document Type: Review

References (43)

1. Chiou WL. The rate and extent of oral bioavailability versus the rate and extent of oral absorption: clarification and recommendation of terminology. J Pharmacokinet Biopharm 2001;28:3-6
2. Balimane PV, Chong S, Morrison RA. Current methodologies used for evaluation of intestinal permeability and absorption. J Phamacol Toxicol Methods 2000;44:301-12
3. Balimane PV, Han YH, Chong S. Current industrial practices of assessing permeability and P-glycoprotein interaction. AAPS J 2006;8:E1-13
4. Bergstrom CAS. In silico predictions of drug solubility and permeability: two rate-limiting barriers to oral drug absorption. Basic Clin Pharmacol Toxicol 2005;96:156-61
5. Artursson P. Cell cultures as models for drug absorption across the intestinal mucosa. Crit Rev Ther Drug Carrier Syst 1991;8:305-30
6. Artursson P, Palm K, Luthman K. Effect of molecular charge on intestinal epithelial drug transport: pH-dependent transport of cationic drugs. Adv Drug Deliv Rev 2001;46:27-43
7. Borchardt R. application of cell culture systems in drug discovery and development. J Drug Target 1995;3:179-82
8. Hidalgo I, Raub T, Borchardt R. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 1989;96:736-49
9. Rubas W, Jezyk N, Grass GM. Comparison of the permeability characteristics of a human colonic epithelial (Caco-2) cell line to colon of rabbit, monkey, and dog intestine and human drug absorption. Pharm Res 1993;10:113-8
10. Artursson P, Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun 1991;175:880-5
11. Chong S, Dando S, Morrison RA. Evaluation of Biocoat intestinal epithelium differentiation environment (3-day cultured Caco-2 cells) as an absorption screening model with improved productivity. Pharm Res 1997;14:1835-7
12. Walter E, Kissel T. Transport of peptidomimetic renin inhibitors across monolayers of a human intestinal cell line (Caco-2): evidence for self-enhancement of paracellular transport route. J Pharm Sci 1995;3:215-30
13. Artursson P, Borchardt RT. Intestinal drug absorption and metabolism in cell cultures: Caco-2 and beyond. Pharm Res 1997;14:1655-8
14. Artursson P, Lindmark T, Davis SS, Illum L. Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm Res 1994;11:1358-61
15. Thummel KE, Shen DD. Design and optimization of dosage regimens: pharmacokinetic data. In: Hardman JG, Limbard LE, Gilman AG, editors, The pharmacological basis of therapeutics. 10th edition. New York: McGraw-Hill; 2001. p. 1927-2023
16. Bailey CA, Bryla P, Malick AW. The use of the intestinal epithelial cell culture model, Caco-2, in pharmaceutical development. Adv Drug Del Rev 1996;22:85-103
17. Yamashita s, Furubayashi T, Kataoka M, et al. Optimized conditions for prediction of intestinal drug permeability using caco-2 cells. Eur J Pharm Sci 2000;10:195-204
18. Food and Drugs Administration. The biopharmaceutics classification system (BCS) guidance. Center for Drug Evaluation and Research (CDER)
19. Adachi Y, Suzuki H, Sugiyama Y. Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res 2001;18:1660-8
20. Breedveld P, Beijnen JH, Schellens JH. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol Sci 2006;27:17-24
21. Yao HM, Chiou WL. The complexity of intestinal absorption and exsorption of digoxin in rats. Int J Pharm 2006;322:79-86
22. Loor F, Tiberghien F, Wenandy T, et al. Cyclosporins: structure-activity relationships for the inhibition of the human FPR1 formylpeptide receptor. J Med Chem 2002;45:4598-612
23. Mallants R, Van Oosterwyck K, Van Vaeck L, et al. Multidrug resistance-associated protein 2 (MRP2) affects hepatobiliary elimination but not the intestinal disposition of tenofovir disoproxil fumarate and its metabolites. Xenobiotica 2005;35:1055-66
24. Chong S, Dando S, Soucek K, Morrison RA. In vitro permeability through caco-2 cells is not quantitatively predictive of in vivo absorption for peptide-like drugs absorbed via the dipeptide transporter system. Pharm Res 1996;13:120-3
25. Sun D, Lennernas H, Welage LS, et al. Comparison of human duodenum and caco-2 gene expression profiles for 12000 gene sequences tags and correlation with permeability of 26 drugs. Pharm Res 2002;19:1400-16
26. Bourdet DL, Pollack GM, Thakker DR. Intestinal absorptive transport of the hydrophilic cation ranitidine: a kinetic modeling approach to elucidate the role of uptake and efflux transporters and paracellular vs. transcellular transport in Caco-2 cells. Pharm Res 2006;23:1178-87
27. Saha P, Kou J. Effect of bovine serum albumin on drug permeability estimation across Caco-2 monolayers. Eur J Pharm Biopharm 2002;54:319-24
28. Tavelin S, Milovic V, Ocklind G, et al. A conditionally immortalized epithelial cell line for studies of intestinal drug transport. J Pharmacol Exp Ther 1999;290:1212-21
29. Cho M, Thompson D, Cramer C, et al. The Madin Darby canine kidney (MDCK) epithelial cell monolayer as a model cellular transport barrier. Pharm Res 1989;6:71-7
30. Lipinski CA, Lombardo F, Dominy BW, Feneey PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001;46:3-26
31. Li C, Latha N, Liu T, et al. Correlation between PAMPA permeability and cellular activities of hepatitis C virus protease inhibitors. Biochem Pharm 2008;75:1186-97
32. De Zwart LL, Rompelberg CJM, Sips AJAM, et al. Anatomical and physiological differences between various species used in studies on the pharmacokinetics and toxicology of xenobiotics.: National Institutes of Public Health and the Environment; 1999. October 1999, RIVM report no. 623860010. Bilthoven, The Netherlands
33. Cheng K-C, Korfmacher W, White RE, Njoroge FG. Lead optimization in discovery drug metabolism and pharmacokinetics. Case study: the hepatitis C virus (HCV) protease inhibitor SCH 503034. Perspect Med Chem 2007;1:1-9
34. Hurst S, Loi CM, Brodfuehrer J, El-Kattan A. Impact of physiological, physicochemical and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans. Expert Opin Drug Metab Toxicol 2007;3:469-89
35. Kararli TT. Comparison of the gastrointestinal anatomy, physiology and biochemistry of humans and commonly used laboratory animals. Biopharm Drug Dispos 1995;16:351-80
36. Fagerholm U, Johansson M, Lannernas H. Comparison between permeability coefficients in rat and human jejunum. Pharm Res 1996;13:1336-42
37. Chiou WL, Barve A. Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats. Pharm Res 1998;15:1792-5
38. Ward KW, Nagilla R, Jolivette LJ. Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human. Xenobiotica 2005;35:191-210
39. Dressman JB. Comparison of canine and human gastrointestinal physiology. Pharm Res 1986;3:123-31
40. Kalantzi L, Persson E, Polentarutti B, et al. Canine intestinal contents vs simulated media for the assessment of solubility of two weak bases in the human small intestinal contents. Pharm Res 2006;23:1373-81
41. Lin JH. Species similarities and differences in pharmacokinetics. Drug Metab Dispos 1995;23:1008-21
42. Chiou WL, Jeong HY, Chung SM, Wu TC. Evaluation of using dog as an animal model to study the fraction of oral dose absorbed of 43 drugs in humans. Pharm Res 2000;17:135-40
43. Chiou WI, Buehler PW. Comparison of oral absorption and bioavailability of drugs between monkey and human. Pharm Res 2002;19:868-73